PMID- 35993651
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20221214
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 15
DP  - 2022 Aug
TI  - Short-term efficacy and safety of edoxaban for venous thromboembolism after total 
      hip or knee arthroplasty: a systematic review and meta-analysis.
PG  - 5540-5552
LID - 29425 [pii]
LID - 10.26355/eurrev_202208_29425 [doi]
AB  - OBJECTIVE: Previous preliminary clinical trials have confirmed that edoxaban can 
      be efficacious for venous thromboembolism (VTE). This meta-analysis was 
      considered to evaluate edoxaban's short-term efficacy and safety for venous 
      thromboembolism after arthroplasty. MATERIALS AND METHODS: A comprehensive search 
      was performed in these databases: PubMed, MEDLINE, Web of Science, and EMBASE on 
      March 2022. All eligible trials should be randomized controlled trials (RCTs) 
      when evaluating short-term efficacy and safety outcomes of edoxaban for VTE after 
      total hip or knee arthroplasty. RESULTS: Nine RCTs with 4274 patients were 
      involved in this meta-analysis. Edoxaban in the VTE group prevented the incidence 
      of VTE and indicated valuable clinical efficacy. The incidence of adverse events 
      (AEs) and adverse drug reactions (ADRs) in the edoxaban group was decreased than 
      that in other groups. Edoxaban increased the incidence of all bleeding events. 
      However, in the edoxaban group and other groups, there was no statistical 
      difference between major bleeding events and clinically relevant non-major or 
      minor bleeding events. Edoxaban subgroups included edoxaban 15 mg, edoxaban 30 mg 
      and edoxaban 60 mg prevented the incidence of VTE. Edoxaban 30 mg and 60 mg group 
      increased the risk of all bleeding events. Edoxaban 30 mg can increase the 
      incidence of major bleeding events. There was no difference in clinically 
      relevant non-major or minor bleeding events. Edoxaban 30 mg can decrease the 
      incidence of AEs. CONCLUSIONS: Edoxaban was an efficacious and safe option to 
      prevent and treat VTE in patients undergoing arthroplasty. However, we need 
      further trials to explore edoxaban's long-term efficacy and safety.
FAU - Li, J-L
AU  - Li JL
AD  - First School of Clinical Medicine, Guangzhou University of Chinese Medicine, 
      Baiyun District, Guangzhou, China. hipknee@163.com.
FAU - Zhang, M
AU  - Zhang M
FAU - Mai, J-L
AU  - Mai JL
FAU - Ma, Y-H
AU  - Ma YH
FAU - Gong, D-W
AU  - Gong DW
FAU - Chen, S
AU  - Chen S
FAU - Xiao, J-C
AU  - Xiao JC
FAU - Wang, H-B
AU  - Wang HB
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Anticoagulants)
RN  - 0 (Pyridines)
RN  - 0 (Thiazoles)
RN  - NDU3J18APO (edoxaban)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - *Arthroplasty, Replacement, Knee/adverse effects
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Pyridines
MH  - Thiazoles
MH  - *Venous Thromboembolism/drug therapy/etiology/prevention & control
EDAT- 2022/08/23 06:00
MHDA- 2022/08/24 06:00
CRDT- 2022/08/22 08:42
PHST- 2022/08/22 08:42 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
AID - 29425 [pii]
AID - 10.26355/eurrev_202208_29425 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 Aug;26(15):5540-5552. doi: 
      10.26355/eurrev_202208_29425.